

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of August, 2019

**Commission file number: 001-37891**

**AC IMMUNE SA**

(Exact Name of Registrant as Specified in Its Charter)

**EPFL Innovation Park  
Building B  
1015 Lausanne, Switzerland**  
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  No

---

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**AC IMMUNE SA**

By: /s/ Andrea Pfeifer  
Name: Andrea Pfeifer  
Title: Chief Executive Officer

By: /s/ Joerg Hornstein  
Name: Joerg Hornstein  
Title: Chief Financial Officer

Date: August 14, 2019

## EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>
99.1	Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the Three and Six Months Ended June 30, 2019
99.2	Management's Discussion and Analysis of Financial Condition and Results of Operations
99.3	Press Release dated August 14, 2019

**Interim Condensed Financial Statements (Unaudited)**

**Interim Condensed Financial  
Statements (Unaudited) (IFRS) as of and for the Three and Six Months Ended June 30, 2019**

AC Immune SA  
EPFL Innovation Park  
Building B  
1015 Lausanne  
Switzerland

## Balance Sheets

	Notes	As of June 30, 2019	As of December 31, 2018
(in CHF thousands)			
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property, plant and equipment	6	3,594	3,324
Right-of-use assets	7	1,978	—
Long-term financial assets	9	304	304
<b>Total non-current assets</b>		<b>5,876</b>	<b>3,628</b>
<b>Current assets</b>			
Prepaid expenses	8	2,917	2,364
Accrued income	3	547	3,667
Finance receivable	10	98	199
Other current receivables		1,049	236
Short-term financial assets	9	80,000	30,000
Cash and cash equivalents	9	205,735	156,462
<b>Total current assets</b>		<b>290,346</b>	<b>192,928</b>
<b>Total assets</b>		<b>296,222</b>	<b>196,556</b>
<b>SHAREHOLDERS' EQUITY AND LIABILITIES</b>			
<b>Shareholders' equity</b>			
Share capital		1,436	1,351
Share premium		346,024	298,149
Accumulated losses		(74,170)	(121,877)
<b>Total shareholders' equity</b>		<b>273,290</b>	<b>177,623</b>
<b>Non-current liabilities</b>			
Long-term financing obligation	10	256	186
Long-term lease liabilities	7	1,559	—
Long-term deferred income	3	1,903	—
Net employee defined benefit liabilities		5,954	5,665
<b>Total non-current liabilities</b>		<b>9,672</b>	<b>5,851</b>
<b>Current liabilities</b>			
Trade and other payables		156	1,979
Accrued expenses		8,414	10,420
Short-term deferred income	3	3,941	351
Short-term debt obligation	10	329	332
Short-term lease liabilities	7	420	—
<b>Total current liabilities</b>		<b>13,260</b>	<b>13,082</b>
<b>Total liabilities</b>		<b>22,932</b>	<b>18,933</b>
<b>Total shareholders' equity and liabilities</b>		<b>296,222</b>	<b>196,556</b>

The accompanying notes form an integral part of these Interim Condensed Financial Statements (Unaudited).

## Statements of Income/(Loss)

	Notes	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
		2019	2018	2019	2018
(in CHF thousands except for per share data)					
<b>Revenue</b>					
Contract revenue	3	1,511	2,028	76,553	3,486
<b>Total revenue</b>		<b>1,511</b>	<b>2,028</b>	<b>76,553</b>	<b>3,486</b>
<b>Operating expenses</b>					
Research & development expenses		(12,700)	(10,533)	(24,293)	(20,604)
General & administrative expenses		(3,585)	(3,065)	(6,879)	(5,770)
<b>Total operating expenses</b>		<b>(16,285)</b>	<b>(13,598)</b>	<b>(31,172)</b>	<b>(26,374)</b>
<b>Operating income/(loss)</b>		<b>(14,774)</b>	<b>(11,570)</b>	<b>45,381</b>	<b>(22,888)</b>
Finance income/(expense), net		(1,732)	447	(1,812)	165
Change in fair value of conversion feature		36	—	4,542	—
Interest income		75	2	164	3
Interest expense		(504)	(22)	(1,601)	(35)
<b>Finance result, net</b>	9	<b>(2,125)</b>	<b>427</b>	<b>1,293</b>	<b>133</b>
<b>Income/(loss) before tax</b>		<b>(16,899)</b>	<b>(11,143)</b>	<b>46,674</b>	<b>(22,755)</b>
<b>Income tax expense</b>		<b>—</b>	<b>—</b>	<b>—</b>	<b>—</b>
<b>Income/(loss) for the period</b>		<b>(16,899)</b>	<b>(11,143)</b>	<b>46,674</b>	<b>(22,755)</b>
Income/(loss) per share (EPS):					
Basic income/(loss) for the period attributable to equity holders	5	(0.24)	(0.19)	0.67	(0.40)
Diluted income/(loss) for the period attributable to equity holders		(0.24)	(0.19)	0.67	(0.40)

## Statements of Comprehensive Income/(Loss)

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2019	2018	2019	2018
(in CHF thousands)				
Income/(loss) for the period	(16,899)	(11,143)	46,674	(22,755)
Other comprehensive income/(loss) not to be reclassified to income or loss in subsequent periods (net of tax):				
Re-measurement losses on defined benefit plans	—	—	—	—
<b>Total comprehensive income/(loss), net of tax</b>	<b>(16,899)</b>	<b>(11,143)</b>	<b>46,674</b>	<b>(22,755)</b>

The accompanying notes form an integral part of these Interim Condensed Financial Statements (Unaudited).

## Statements of Changes in Equity

	Share capital	Share premium	Accumulated losses	Total
	(in CHF thousands)			
<b>Balance as of January 1, 2018</b>	<b>1,147</b>	<b>188,299</b>	<b>(72,607)</b>	<b>116,839</b>
Net loss for the period	—	—	(22,755)	(22,755)
Other comprehensive loss	—	—	—	—
Total comprehensive loss	—	—	(22,755)	(22,755)
Share-based payments	—	—	1,314	1,314
Issuance of shares:				
restricted share awards	—	115	(115)	—
exercise of options	2	14	—	16
transaction costs	—	(21)	—	(21)
<b>Balance as of June 30, 2018</b>	<b>1,149</b>	<b>188,407</b>	<b>(94,163)</b>	<b>95,393</b>

	Notes	Share capital	Share premium	Accumulated losses	Total
		(in CHF thousands)			
<b>Balance as of January 1, 2019</b>		<b>1,351</b>	<b>298,149</b>	<b>(121,877)</b>	<b>177,623</b>
Net income for the period		—	—	46,674	46,674
Other comprehensive income		—	—	—	—
Total comprehensive income		—	—	46,674	46,674
Share-based payments		—	—	1,146	1,146
Issuance of shares:					
conversion of note agreement, net of transaction costs	4	73	47,705	—	47,778
restricted share awards		—	113	(113)	—
exercise of options, net of transaction costs		12	57	—	69
<b>Balance as of June 30, 2019</b>		<b>1,436</b>	<b>346,024</b>	<b>(74,170)</b>	<b>273,290</b>

The accompanying notes form an integral part of these Interim Condensed Financial Statements (Unaudited).

## Statements of Cash Flows

	Notes	For the Six Months Ended June 30,	
		2019	2018
(in CHF thousands)			
<b>Operating activities</b>			
Net income/(loss) for the period		46,674	(22,755)
<b>Adjustments to reconcile net loss for the period to net cash flows:</b>			
Depreciation of property, plant and equipment	6	584	443
Depreciation of right-of-use assets	7	207	—
Finance expense, net	11	1,648	(133)
Share-based compensation expense		1,146	1,314
Changes in net employee defined benefit liability		289	276
Change in fair value of conversion feature	11	(4,542)	—
Interest expense	11	1,601	24
<b>Changes in working capital:</b>			
(Increase) in prepaid expenses	8	(553)	(1,733)
Decrease in accrued income		3,120	168
(Increase)/decrease in other current receivables		(838)	496
(Decrease)/increase in accrued expenses		(2,085)	422
Increase in deferred income	3	5,488	95
Increase/(decrease) in trade and other payables		(1,861)	967
<b>Cash provided by/(used in) operating activities</b>		<b>50,878</b>	<b>(20,416)</b>
Interest income		164	3
Interest paid		(86)	—
Financial costs		(7)	(68)
<b>Net cash flows provided by/(used in) operating activities</b>		<b>50,949</b>	<b>(20,481)</b>
<b>Investing activities</b>			
Short-term financial assets	9	(50,000)	—
Purchases of property, plant and equipment	6	(850)	(1,486)
Rent deposit		—	(84)
<b>Net cash flows used in investing activities</b>		<b>(50,850)</b>	<b>(1,570)</b>
<b>Financing activities</b>			
Proceeds from issuance of convertible loan	4	50,278	—
Principal payments of lease obligations	7	(206)	—
Transaction costs on issuance of shares		(510)	(21)
Proceeds from issuance of common shares – option plan		69	16
Proceeds from long term financing	10	101	148
<b>Net cash flows provided by financing activities</b>		<b>49,732</b>	<b>143</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>		<b>49,831</b>	<b>(21,908)</b>
Cash and cash equivalents at January 1		156,462	124,377
Exchange gain/(loss) on cash and cash equivalents		(558)	195
Cash and cash equivalents at June 30		205,735	102,664
<b>Net increase/(decrease) in cash and cash equivalents</b>		<b>49,831</b>	<b>(21,908)</b>

### Additional Information:

The Company settled its convertible loan via equity for CHF 48.3 million, gross of CHF 510 thousand for transaction costs. The acquisition of CHF 22 thousand of property, plant and equipment purchases was non-cash and recorded within trade and other payables.

The accompanying notes form an integral part of these Interim Condensed Financial Statements (unaudited)



**Notes to the Interim Condensed Financial Statements (Unaudited)**  
**(in CHF thousands, except share and per share amounts)**

**1. Corporate information**

AC Immune SA (the “Company,” or “AC Immune,” “ACIU,” “we,” “our,” “ours,” “us”) is a clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. Misfolded proteins are generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer’s disease, or AD, and Parkinson’s disease, or PD, with common mechanisms and drug targets, such as Abeta, Tau and alpha-synuclein. Our corporate strategy is founded upon a three-pillar approach that targets Alzheimer’s disease, non-Alzheimer’s neurodegenerative diseases including NeuroOrphan indications and diagnostics. We use our two unique proprietary platform technologies, SupraAntigen™ (conformation-specific biologics) and Morphomer™ (conformation-specific small molecules), to discover, design and develop novel medicines and diagnostics to target misfolded proteins.

The interim condensed financial statements of AC Immune SA as of and for the three and six months ended June 30, 2019 were authorized for issuance by the Company’s Audit Committee on August 12, 2019.

**2. Basis of preparation and changes to the Company’s accounting policies**

**Statement of compliance**

These interim condensed financial statements as of and for the three and six months ended June 30, 2019 have been prepared in accordance with International Accounting Standard 34 (IAS 34), *Interim Financial Reporting*, and such financial information should be read in conjunction with the audited financial statements in the Company’s Annual Report on Form 20-F for the year ended December 31, 2018, and any public announcements made by the Company during the interim reporting period.

**Basis of measurement**

The financial statements have been prepared under the historical cost convention.

**Revenue recognition**

The Company enters into licensing agreements which are within the scope of IFRS 15, under which it licenses certain proprietary rights to its product candidates and intellectual property (“IP”) to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and/or commercial milestone payments; payments for research and clinical services the Company provides through either its full-time employees or third-party vendors; and royalties on net sales of licensed commercialized products depending on the Company’s IP. Each of these payments results in license, collaboration and other revenues, which are classified as contract revenue on the statements of income/(loss), except for revenues from royalties on net sales of commercialized products depending on the Company’s IP, which are classified as royalty revenues.

*Licenses on intellectual property:* If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are sold in conjunction with a related service, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the performance obligation is settled over time, the Company determines the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

*Milestone payments:* At the inception of each arrangement that includes development, regulatory and/or commercial milestone payments, the Company evaluates whether the milestones are considered highly probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is highly probable that a significant revenue reversal would not occur in future periods, the associated milestone

value is included in the transaction price. These amounts for the performance obligations under the contract are recognized as they are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments recorded would affect contract revenues and earnings in the period of adjustment.

*Research and development services:* The Company has certain arrangements with our collaboration partners that include contracting our full-time employees for research and development programs. The Company assesses if these services are considered distinct in the context of each contract and, if so, they are accounted for as separate performance obligations. These revenues are recorded in contract revenue as the services are performed.

*Sublicense revenues:* The Company has certain arrangements with our collaboration partners that include provisions for sublicensing. The Company recognizes any sublicense revenues at the point in time it is highly probable to obtain and not subject to reversal in the future.

*Royalties:* For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing and collaboration agreements.

*Contract balances:* The Company receives payments and determines credit terms from its licensees for its various performance obligations based on billing schedules established in each contract. The timing of revenue recognition, billings and cash collections results in billed other current receivables, accrued income (contract assets), and deferred income (contract liabilities) on the balance sheet. Amounts are recorded as other current receivables when the Company's right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.

### **Critical judgments and accounting estimates**

The preparation of the Company's interim condensed financial statements in conformity with IAS 34 requires management to make judgments, estimates and assumptions that affect the amounts reported in the interim condensed financial statements and accompanying notes and the related application of accounting policies as it relates to the reported amounts of assets, liabilities, income and expenses.

The areas where AC Immune has had to make judgments, estimates and assumptions relate to (i) revenue recognition on licensing and collaboration agreements, (ii) clinical development accruals, (iii) net employee defined benefit liability, (iv) income taxes, (v) share-based compensation and (vi) right-of-use assets and lease liabilities. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised.

### **Accounting policies, new standards, interpretations and amendments adopted by the Company**

The accounting policies adopted in the preparation of the interim condensed financial statements are consistent with those followed in the preparation of the Company's annual financial statements for the year ended December 31, 2018, except for the adoption of new standards and interpretations effective as of January 1, 2019. The Company has not adopted any other standard, interpretation or amendment that has been issued but is not yet effective.

#### ***Recent accounting pronouncements – recently adopted***

##### *IFRS 16 – Leases*

Effective January 1, 2019, the Company adopted IFRS 16 Leases which provides a new model for lessee accounting in which all leases, other than short-term and low-value leases, are accounted for by the recognition on the balance sheet of a right-of-use asset and a lease liability, and the subsequent amortization of the right-of-use asset over the earlier of the end of the useful life or the lease term. The Company applied the modified retrospective approach, which requires the recognition of the cumulative effect of initially applying IFRS 16 as of January 1, 2019 to accumulated losses and not to restate prior years. Since the Company recognized the right-of-use assets at the

amount equal to the lease liabilities there was no impact to accumulated losses. For a complete discussion of accounting, see Note 7, “Right-of-use assets and lease liabilities.”

The Company has elected to apply the following practical expedients in adopting IFRS 16: (i) not to recognize right-of-use assets and lease liabilities for leases of low value (i.e. approximate fair value of USD 5,000), (ii) to apply a single discount rate to our property leases and to our portfolio of office equipment leases, respectively, (iii) to apply hindsight in determining the lease term for contracts which contain certain options to extend or terminate the lease, (iv) to account for each lease component and any non-lease components as a single lease component and (v) to rely on our assessment of whether leases were onerous by applying IAS 37 *Provisions, Contingent Liabilities and Contingent Assets* immediately before the date of application. The Company’s weighted average incremental borrowing rate calculated as of January 1, 2019 was 2.54%.

The following table reconciles the Company’s operating lease obligations at December 31, 2018, as previously disclosed in the Company’s consolidated financial statements on Form 20-F, to the lease obligations recognized on initial application of IFRS 16 at January 1, 2019.

	<b>(in CHF thousands)</b>
Operating lease commitments at December 31, 2018	861
Discounted using the incremental borrowing rate at January 1, 2019	847
Recognition exemption for short-term leases	(535)
Recognition exemption for leases of low value	—
Extension options reasonably certain to be exercised	1,873
<b>Lease obligation recognized at January 1, 2019</b>	<b>2,185</b>

In accordance with the adoption of IFRS 16 *Leases* as of January 1, 2019, the Company recorded at initial recognition a non-cash CHF 2.2 million right-of-use asset and corresponding lease liability. Comparative information has not been restated. The Company’s statement of loss for the three and six months ended June 30, 2019 was impacted by an increase for depreciation of right-of-use of leased assets CHF 0.1 million and CHF 0.2 million, respectively. The impact for interest expense was less than CHF 0.1 million for both periods, respectively. During the same periods, the Company’s cash flow statement was impacted by a shift from the cash generated from operations of CHF 0.2 million to the net cash used in financing activities. Overall, IFRS 16 was cash flow neutral for the Company.

The Company made the following changes in presentation: in the balance sheets, additional line items to reflect the right-of-use assets, the non-current and the current lease liabilities and in the statement of cash flows, additional line items related to the depreciation of the right-of-use of leased assets and repayment of the principal portion of the lease payments.

#### *Impact on accounting for leases*

At inception of a leasing contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Company recognizes a right-of-use asset and a lease liability at the lease commencement date. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. The Company generally uses the rate implicit in the contract or its incremental borrowing rate. Lease payments generally are fixed for the contract term. The lease liability is measured at amortized cost using the effective interest method. The lease liability is remeasured if there is change in the estimated lease term, a change in future lease payments arising from a change in an index or rate, a change in the Company’s estimate of the amount expected to be payable under a residual value guarantee, or a change in assessment of whether it will exercise a purchase, extension or termination option.

The estimated lease term by right-of-use asset categories are as follows:

Buildings	5 years
Office equipment	5 years

At inception, the right-of-use asset comprises the initial lease liability and any initial direct costs. The right-of-use asset is depreciated over the shorter of the lease term or the useful life of the underlying asset. The right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

Both the right-of-use-assets and lease liabilities are recognized in the balance sheets.

#### Accounting pronouncements – not yet adopted

There are no standards that are not yet effective and that would be expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.

#### Going concern

The Company believes it will be able to meet all of its obligations as they fall due for at least 12 months from June 30, 2019 after considering the Company's cash position of CHF 206 million and short-term financial assets of CHF 80 million as of June 30, 2019. Hence, the unaudited interim condensed financial statements have been prepared on a going concern basis.

To date, the Company has financed its cash requirements primarily from its public offerings, share issuances and revenues from license and collaboration agreements. The Company is a clinical stage company and is exposed to all the risks inherent to establishing a business. Inherent to the Company's business are various risks and uncertainties, including the substantial uncertainty as to whether current projects will succeed. The Company's success may depend in part upon its ability to (i) establish and maintain a strong IP position and protection, (ii) enter into collaborations with partners in the biotech and pharmaceutical industry, (iii) successfully move its product candidates through clinical development, (iv) attract and retain key personnel, and (v) acquire capital to support its operations.

#### 3. Revenues

AC Immune generated revenues of CHF 1.5 million and CHF 76.6 million in the three and six months ended June 30, 2019, a decrease of CHF 0.5 million and an increase of CHF 73.1 million over the comparable periods in 2018, respectively.

	For the Three Months Ended June 30,	
	2019	2018
	(in CHF thousands)	
Eli Lilly	433	—
Genentech	—	—
Janssen	648	528
Life Molecular Imaging	—	—
Biogen	124	1,216
Other	306	284
<b>Total contract revenue</b>	<b>1,511</b>	<b>2,028</b>

	<b>For the Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>
	<b>(in CHF thousands)</b>	
Eli Lilly	74,300	—
Genentech	—	—
Janssen	673	771
Life Molecular Imaging	—	—
Biogen	1,063	2,150
Other	517	565
<b>Total contract revenue</b>	<b>76,553</b>	<b>3,486</b>

### 3.1 Licensing and collaboration agreements

The following table presents changes in the Company's contract assets and liabilities during the six months ended June 30, 2019 and 2018:

	<b>Balance at the beginning of the reporting period</b>	<b>Additions</b>	<b>Deductions</b>	<b>Balance at the end of the reporting period</b>
	<b>(in CHF thousands)</b>			
<b>Six months ended June 30, 2019:</b>				
Accrued income	3,667	1,296	(4,416)	547
Deferred income	351	7,121	(1,628)	5,844
<b>Six months ended June 30, 2018:</b>				
Accrued income	2,799	2,723	(2,891)	2,631
Deferred income	355	909	(796)	468

During the three and six months ended June 30, 2019 and June 30, 2018, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods:

	<b>For the Three Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>
	<b>(in CHF thousands)</b>	
<b>Revenue recognized in the period from:</b>		
Amounts included in the contract liability at the beginning of the period	466	417
Performance obligations satisfied in previous periods	—	—

	<b>For the Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>
	<b>(in CHF thousands)</b>	
<b>Revenue recognized in the period from:</b>		
Amounts included in the contract liability at the beginning of the period	356	813
Performance obligations satisfied in previous periods	—	—

#### *Tau Morphomer Small Molecule – 2018 license agreement with Eli Lilly and Company*

In December 2018, we entered into an exclusive, worldwide licensing agreement with Eli Lilly and Company ("Lilly") to research and develop Tau Morphomer small molecules for the treatment of Alzheimer's disease and other neurodegenerative diseases. The agreement became effective on January 23, 2019 when the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired.

Per the terms of the agreement, the Company received an initial upfront payment of CHF 80 million in February 2019. The Company is conducting the development of Tau Morphomer small molecules through the completion of Phase 1, with activities commencing in the first half of 2019. Lilly will lead and fund further clinical development and will retain global commercialization rights for all indications, including Alzheimer's disease, Progressive Supranuclear Palsy and other neurodegenerative diseases.

Per the terms of the agreement, the Company may become eligible to receive additional milestone payments totaling up to approximately CHF 840 million for clinical and regulatory milestones and CHF 900 million upon achievement of certain commercial milestones. In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the low-double digits to the mid-teens. The agreement will terminate by the date of expiration of the last royalty term for the last licensed product. However, under the terms of the agreement, Lilly may terminate the agreement at any time after completion of the Lilly Pre-Clinical Activities Period by providing three months' notice to us.

AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Lilly is a customer. The Company identified the following significant performance obligations under the contract: (i) a right-of-use license and (ii) research and development activities outlined in the development plan. The valuation of each performance obligation involves estimates and assumptions with revenue recognition timing to be determined either by delivery or the provision of services.

The Company used the residual approach to estimate the selling price for the right-of-use license and an expected cost plus margin approach for estimating the research and development activities. The right-of-use license was delivered on the effective date. The research and development activities are expected to be delivered over time as the services are performed. For these services, revenue will be recognized over time using the input method, based on costs incurred to perform the services, since the level of costs incurred over time is thought to best reflect the transfer of services to Lilly. The Company determined the value of the research and development activities to be CHF 6.9 million and deferred this balance from the effective date. As of June 30, 2019, the Company has released CHF 1.2 million of deferred income (contract liability) yielding a balance of CHF 5.7 million of which CHF 1.9 million is long-term. The remaining CHF 73.1 million from the upfront payment was allocated to the right-of-use license and recognized on the effective date.

At inception, none of the clinical, regulatory or commercial milestones had been included in the transaction price, as all milestone amounts were fully constrained. In assessing that future clinical, regulatory or commercial milestones are fully constrained, the Company considered numerous factors to determine that these milestones are not highly probable to obtain, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee's efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Lilly and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

#### *Anti-Abeta antibody in AD – 2006 agreement with Genentech*

In November 2006, we signed an exclusive, worldwide licensing agreement for crenezumab, our humanized monoclonal antibody targeting misfolded Abeta. The value of this partnership is potentially greater than USD 340 (CHF 336) million.

The term of the agreement commenced on the Effective Date and, unless sooner terminated by mutual agreement or pursuant to any other provision of the agreement, terminates on the date on which all obligations between the Parties with respect to the payment of milestones or royalties with respect to Licensed Products have passed or expired. Either party may terminate the agreement for any material breach by the other Party, provided a cure period of 90 days from the date notice is given.

Genentech commenced a first Phase 3 clinical study in March 2016 for crenezumab (CREAD 1). In March 2017, Genentech started a second Phase 3 clinical trial (CREAD 2). Since 2013, Crenezumab is also studied in a Phase 2 trial in individuals who carry the PSEN1 E280A autosomal-dominant mutation and do not meet the criteria for mild cognitive impairment due to AD or dementia due to AD and are, thus, in a preclinical phase of AD (autosomal dominant AD (ADAD)). In 2019, Genentech initiated a Tau Positron Emission Tomography

(PET) substudy to the ongoing Phase 2 trial in ADAD to evaluate the effect of crenezumab on tau burden which may also increase the understanding of disease progression in the preclinical stage of ADAD.

If crenezumab receives regulatory approval, we will be entitled to receive royalties that are tied to annual sales volumes with different royalty rates applicable in the U.S. and Europe. To date, we have received total milestone payments of USD 65 million (CHF 70.1 million) comprised of a USD 25 (CHF 31.6) million up-front payment and USD 40 (CHF 38.2) million for clinical development milestones achieved all in prior to January 1, 2017. Genentech may terminate the agreement at any time by providing three months' notice to us. In such event all costs incurred are still refundable.

AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Genentech is a customer. The Company identified the following performance obligations under the contract: (i) a right-of-use license and (ii) conduct of research under a research plan. The Company considered the research and development capabilities of Genentech and Genentech's right to sublicense to conclude that the license has stand-alone functionality and is distinct. The Company's obligation to perform research does not significantly impact or modify the licenses' granted functionality.

At execution of the agreement, the transaction price included the USD 25 (CHF 31.6) million up-front consideration received. At inception, none of the clinical or regulatory milestones had been included in the transaction price, as all milestone amounts were fully constrained. The Company has received three milestone payments since inception totaling USD 40 (CHF 38.2) million. The Company could receive greater than USD 275 (CHF 272) million or more for further regulatory milestones for this exclusive, worldwide alliance. In assessing that future regulatory milestones are fully constrained, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee's efforts. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Genentech and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

On January 30, 2019, we announced that Roche, the parent of Genentech, is discontinuing the CREAD 1 and CREAD 2 (BN29552 and BN29553) Phase III studies of crenezumab in people with prodromal to mild sporadic AD. The decision came after an interim analysis conducted by the Independent Data Monitoring Center ("IDMC") indicated that crenezumab was unlikely to meet its primary endpoint of change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score. This decision was not related to the safety of the investigational product. No safety signals for crenezumab were observed in this analysis and the overall safety profile was similar to that seen in previous trials.

Crenezumab continues to be studied in the Phase 2 preventive trial, which began in 2013, of cognitively healthy individuals in Columbia who carry the PSEN1 E280A autosomal-dominant mutation and are in a preclinical phase of AD (autosomal dominant AD (ADAD)). This study will determine if treating people carrying this mutation with crenezumab prior to the onset of AD symptoms will slow or prevent the decline of cognitive and functional abilities.

For the three and six months ended June 30, 2019 and 2018, we have recognized no revenues from this arrangement.

#### *Anti-Tau antibody in AD – 2012 agreement with Genentech*

In June 2012, we entered into a second agreement with Genentech to research, develop and commercialize our anti-Tau antibodies for use as immunotherapeutics. The value of this exclusive, worldwide alliance is potentially greater than CHF 400 million and includes upfront and clinical, regulatory and commercial milestone payments. In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the mid-single digits to the high-single digits. The agreement also provides for collaboration on two additional indications built on the same anti-Tau antibody program as well as potential anti-Tau diagnostic products.

The term of the agreement commenced on the Effective Date and, unless sooner terminated by mutual agreement or pursuant to any other provision of the agreement, terminates on the date on which all obligations between the Parties with respect to the payment of milestones or royalties with respect to Licensed Products have

passed or expired. Either party may terminate the agreement for any material breach by the other Party, provided a cure period of 90 days from the date notice is given.

To date, we have received payments totaling CHF 59 million, including a CHF 14 million milestone payment received and recognized in the fourth quarter of 2017 associated with the first patient dosing in a Phase 2 clinical trial for Alzheimer's disease with an anti-Tau monoclonal body known as RG6100, a CHF 14 million milestone payment recognized in the second quarter of 2016 and received in July 2016, associated with the announcement of the commencement of the Phase 1 clinical study of the lead anti-Tau antibody candidate and a CHF 14 million milestone payment received in 2015 in connection with the ED-GO decision. As we met all performance obligations on reaching these milestones, we have recognized revenue in the respective periods. Genentech may terminate the agreement at any time by providing three months' notice to us.

AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Genentech is a customer. The Company identified the following performance obligations under the contract: (i) a right-of-use license and (ii) conduct of research under a research plan. The Company considered the research and development capabilities of Genentech and Genentech's right to sublicense to conclude that the license has stand-alone functionality and is distinct. The Company's obligation to perform research does not significantly impact or modify the licenses' granted functionality.

At execution of the agreement, the transaction price included CHF 17 million up-front consideration received. At inception, none of the clinical or regulatory milestones had been included in the transaction price, as all milestone amounts were fully constrained. The Company has received three milestones since inception totaling CHF 42 million. The Company could also receive up to an additional CHF 368.5 million in clinical, regulatory and commercial milestones. In assessing that future clinical, regulatory or commercial milestones are fully constrained, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Genentech and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

For the three and six months ended June 30, 2019 and 2018, we have recognized no revenues from this arrangement.

#### *Tau Vaccine in AD – 2014 agreement with Janssen Pharmaceuticals*

In December 2014, we entered into an agreement with Janssen Pharmaceuticals, Inc. ("Janssen") one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize therapeutic anti-Tau vaccines for the treatment of AD and potentially other Tauopathies. The value of this partnership is potentially up to CHF 500 million and includes upfront and clinical, regulatory and commercial milestones. In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the low-double digits to the mid-teens. In July 2017 and January 2019, the Companies entered into the Second and Third Amendments, respectively. These Amendments allow for the alignment of certain payment and activity provisions with the Development Plan and Research Plan activities. We and Janssen will co-develop second generation lead therapeutic vaccines, ACI-35.030 and JACI-35.054, through Phase 1b/2a completion. AC Immune and Janssen will jointly share R&D costs until the completion of the first Phase 2b. From Phase 2b and onwards, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of the second generation vaccines.

Under the terms of the agreement, Janssen may terminate the agreement at any time after completion of the first Phase 1b clinical study in 2016 by providing 90 days' notice to us. If not otherwise terminated, the agreement shall continue until the expiration of all royalty obligations as outlined in the contract.

The agreement also allows for the expansion to a second indication based on the same anti-Tau vaccine program and based on intellectual property related to this program.

The Company received a CHF 25.9 million up-front, non-refundable license fee which we recognized as revenue in 2014. In May 2016, we received a CHF 4.9 million payment for reaching a clinical milestone in the first



Phase 1b study. As we met all performance obligations on reaching the milestone, we have recognized this income as revenue.

AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Janssen is a customer. The Company identified the following performance obligations under the contract: (i) a right-of-use license and (ii) research and development services including a Development and CMC work plan. The Company considered the research and development capabilities of Janssen, Janssen's right to sublicense, and the fact that the research and development services are not proprietary and can be provided by other vendors, to conclude that the license has stand-alone functionality and is distinct. The Company's obligation to perform research and development services does not significantly impact or modify the licenses' granted functionality. Based on these assessments, the Company identified the license and the research and development services as the performance obligations at the inception of the arrangement, which were deemed to be distinct in the context of the contract.

At execution of the agreement, the transaction price included only the CHF 25.9 million up-front consideration received. At inception, none of the clinical, regulatory or commercial milestones has been included in the transaction price, as all milestone amounts were fully constrained. The Company did receive a CHF 4.9 million payment for reaching a clinical milestone in the first Phase 1b study in May 2016. The Company could also receive up to more than CHF 458 million in clinical, regulatory and commercial milestones as well as tiered, low-double digit to mid-teen royalties on aggregate net sales of products. In assessing that future clinical, regulatory or commercial milestones are fully constrained, the Company considered numerous factors to determine that these milestones are not highly probable to obtain, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee's efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

For the three months ended June 30, 2019 and 2018 we have recognized CHF 0.6 million and CHF 0.5 million, respectively. For the six months ended June 30, 2019 and 2018 we have recognized CHF 0.7 million and CHF 0.8 million, respectively.

*Tau-PET imaging agent in AD – 2014 agreement with Life Molecular Imaging (formerly Piramal Imaging SA)*

In May 2014, we entered into an agreement, our first diagnostic partnership with Life Molecular Imaging ("Life Molecular"), the former Piramal Imaging SA. The partnership with Life Molecular is an exclusive, worldwide licensing agreement for the research, development and commercialization of the Company's Tau protein Positron Emission Tomography (PET) tracers supporting the early diagnosis and clinical management of AD and other Tau-related disorders and includes upfront and sales milestone payments totaling up to EUR 157 (CHF 176) million, plus royalties on sales at a percentage rate ranging from mid-single digits to low double digits.

Life Molecular may terminate this agreement at any time after the first 18 months from the Effective Date of this agreement upon three months prior written notice. If not otherwise terminated, the agreement shall continue until the date of expiration of the last to expire royalty term.

In connection with this agreement, AC Immune received a EUR 500 (CHF 664) thousand payment which was fully recognized in 2015. In Q1 2017, we recorded a EUR 1.0 (CHF 1.1) million milestone related to the initiation of "Part B" of the first-in-man Phase 1 clinical trial for PSP (Progressive Supranuclear Palsy). The Company is eligible to receive variable consideration related to the achievement of certain clinical milestones totaling EUR 6 (CHF 7) million should the compound make it through to Phase 3 clinical studies. We are also eligible to receive potential regulatory and sales based milestones totaling EUR 150 (CHF 168) million. The Company is also eligible for royalties from the mid-single digits to low-double digits.

AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Life Molecular is a customer. The Company has identified that the right-of-use license as the only performance obligation. The Company determined that transaction price based on the defined terms allocated to each performance obligation specified in the contract.

The upfront payment constitutes the amount of consideration to be included in the transaction price and has been allocated to the license. None of the clinical, regulatory and commercial milestones have been included in the transaction price as these variable consideration elements are considered fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee's efforts.

Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Life Molecular and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur. The Company considered Life Molecular's right to sublicense and develop the Tau Protein PET tracers, and the fact that Life Molecular could perform the research and development work themselves within the license term without AC Immune, to conclude that the license has stand-alone functionality and is distinct. The Company believes that the contracted amount represents the fair value. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

For the three and six months ended June 30, 2019 and 2018, the Company has recognized no revenues from this agreement.

*Alpha-synuclein and TDP-43 PET tracers in AD – 2016 agreement with Biogen*

On April 13, 2016, we entered into a non-exclusive research collaboration agreement with Biogen International GmbH, ("Biogen"). Under the agreement, we and Biogen have agreed to collaborate in the research and early clinical development of our alpha-synuclein PET tracer program for Parkinson's disease and other synucleinopathies, and a second program for the identification, research and development of novel PET ligands against TDP-43, a protein recently linked to neurodegeneration in diseases such as amyotrophic lateral sclerosis. In addition, we have agreed to share the costs of the collaboration, with Biogen primarily funding the majority of research costs, subject to a cap, which includes an upfront technology access fee and funding towards research and development personnel. We own all intellectual property rights to any invention relating to alpha-synuclein or TDP-43 PET tracers.

AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Biogen is a customer. The Company has identified two performance obligations in our Biogen collaboration: (i) technology access fee and (ii) research and development services. The Company determined the transaction price based on the defined terms allocated to each performance obligation specified in the contract. In instances where the Company is reimbursed for research and development contributions procured from third parties such as negotiated terms with clinical research organizations, AC Immune records revenues for such services as it is acting as a principal in procuring the goods or services. The Company has the primary responsibility for fulfilling the promise to provide the specified good or service, it has inventory risk before transfer to the customer and it has discretion in negotiating the price with third parties. For other research and development services, revenues are recognized as work is performed, which correspond with, and best depict the transfer of control to the customer in line with the terms outlined in the contract.

For the three months ended June 30, 2019 and 2018, the Company has recognized CHF 0.1 million and CHF 1.2 million, respectively. For the six months ended June 30, 2019 and 2018, the Company has recognized CHF 1.1 million and CHF 2.2 million, respectively. This collaboration concluded on April 13, 2019.

*Recombinant protein therapeutic candidate – 2017 agreement with Essex Bio-Technology Limited*

On May 19, 2017, we entered into a Research Project agreement with Essex Bio-Technology Limited, or Essex, to develop a recombinant protein therapeutic candidate acting on a unique neuroprotective mechanism for treatment of neurological diseases, such as Alzheimer's disease and frontotemporal dementia. Essex will provide joint research commitment as well as financial support to AC Immune for the pre-IND development of the biological agent.

Subject to the terms of this agreement, Essex and the Company have the right to terminate by providing 60 days' notice to the other Party. Otherwise, the agreement shall remain in force until the later of the (i) completion of the Research and Development program or (ii) five years from the Effective date.

As part of this agreement, the parties have agreed to an initial two-year Research Plan, which intends to develop a basic Fibroblast Growth Factor as a therapeutic for the treatment of neurodegenerative diseases and to generate novel antibody therapeutics.

AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Essex Bio-Technology is a customer. AC Immune has identified that its performance obligation is for full-time employees to provide research support.

The transaction price consists of the contractual amounts to recognize for the full-time employee charges. For the full-time employee charges, we recorded revenues throughout the period based on the contractual rates over the service period as this best depicts the transfer of control to Essex.

For the three months ended June 30, 2019 and 2018, the Company has recognized CHF 0.2 million, respectively. For the six months ended June 30, 2019 and 2018, the Company has recognized CHF 0.4 million, respectively. Subject to the progress of the projects, the Company may expect to recognize approximately CHF 0.8 million annually through the end of the contract.

#### *Continuation of 2015 grant from the Michael J. Fox Foundation*

On September 16, 2017, we formally signed a grant continuation with the Michael J. Fox Foundation for Parkinson's disease research ("MJFF"). This grant provides funds for the development of PET tracers for pathological forms of the protein alpha-synuclein, to support the early diagnosis and clinical management of Parkinson's disease. Following the successful completion of this grant extension in 2018, we received an additional grant in November 2018 to conduct a first-in-human ("FiH") study in 2019. This grant aims to facilitate the execution of a FiH study for a potential alpha-synuclein PET tracer with the current lead compound.

As part of the November 2018 grant, the MJFF expects that AC Immune will complete tasks according to the agreed timelines. AC Immune's funding is variable depending on the satisfactory achievement of specific tasks. The Company identified six milestones to achieve and these are outputs of the Company's normal services to develop its PET tracer. The services themselves over time are considered the performance obligation and not each a distinct performance obligation. Therefore, AC Immune has determined it has one performance obligation in the arrangement: the clinical and regulatory services in support of the development of the alpha-synuclein PET tracer.

The transaction price consists of the contractual amount of CHF 0.3 million which is allocated to the services performed. However, the consideration is variable dependent upon AC Immune's completion of key milestones. Using the most likely amount method, AC Immune assessed the project funding and likelihood of milestone obtainment. Management estimated a 100% likelihood of completing all milestones under the terms of the grant and no discount of the transaction price is taken. The Company therefore recognizes the revenues associated with this grant as services are performed. Quarterly, the Company estimates its progress and whether to constrain further revenue recognition. There are no constraints assessed as of June 30, 2019.

For the three months ended June 30, 2019 and 2018, the Company has recognized CHF 0.1 million, respectively. For the six months ended June 30, 2019 and 2018, the Company has recognized CHF 0.2 million, respectively. The Company has also recorded CHF 0.1 million as short-term deferred income. The Company may expect to recognize approximately CHF 0.1 million through the end of this grant extension.

#### **4. Share capital**

The Company and Lilly entered into a convertible note agreement effective January 23, 2019 for USD 50.0 (CHF 50.3) million. On April 25, 2019, the Convertible Note Agreement with Lilly automatically converted in line with the terms of the agreement. As a result of this conversion, 3,615,328 of our common shares were issued to Lilly. This note is now fully settled and there is no further equity or cash consideration due to Lilly thereunder.

## 5. Earnings/(loss) per share

	<b>For the Three Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>
	<b>(in CHF thousands except for share and per share data)</b>	
Net loss attributable to equity holders of the Company	(16,899)	(11,143)
Loss per share (EPS):		
Weighted-average number of shares used to compute EPS basic and diluted attributable to equity holders	70,764,091	57,423,650
Basic and diluted loss for the period attributable to equity holders	(0.24)	(0.19)

	<b>For the Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>
	<b>(in CHF thousands except for share and per share data)</b>	
<b>Basic income/(loss) per share (EPS):</b>		
<b>Numerator:</b>		
Net income/(loss) attributable to equity holders of the Company	46,674	(22,755)
<b>Denominator:</b>		
Weighted-average number of shares outstanding to equity holders	69,351,363	57,395,987
Basic income/(loss) for the period attributable to equity holders	<u>0.67</u>	<u>(0.40)</u>

	<b>For the Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>
<b>Diluted income/(loss) per share (EPS):</b>		
<b>Numerator:</b>		
Net income/(loss) attributable to equity holders of the Company	46,674	(22,755)
<b>Denominator:</b>		
Weighted-average number of shares outstanding to equity holders	69,351,363	57,395,987
Effect of dilutive securities from equity incentive plans	494,495	—
Weighted-average number of shares outstanding – diluted to equity holders	<u>69,845,858</u>	<u>57,395,987</u>
Diluted income/(loss) for the period attributable to equity holders	0.67	(0.40)

Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:

	<b>For the Three Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>
Share options issued and outstanding	335,958	1,396,572
Restricted share awards subject to future vesting	97,642	114,496
Convertible shares	993,222	—

	<b>For the Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>
Share options issued and outstanding	770,068	1,364,166
Restricted share awards subject to future vesting	—	115,242
Convertible shares	1,837,625	—

## 6. Property, plant and equipment

	As of June 30, 2019				Total
	Furniture	Computers /IT	Lab Equipment	Leasehold Improvements	
(in CHF thousands)					
<b>Acquisition cost:</b>					
Balance at the end of the previous year	126	1,025	5,367	350	6,868
Acquisitions	46	190	630	6	872
Disposals	(33)	(129)	(19)	(7)	(188)
Balance at end	<b>139</b>	<b>1,086</b>	<b>5,978</b>	<b>349</b>	<b>7,552</b>
<b>Accumulated depreciation:</b>					
Balance at the end of the previous year	(77)	(455)	(2,857)	(155)	(3,544)
Depreciation expense	(10)	(130)	(416)	(28)	(584)
Disposals	33	113	17	7	170
Balance at end	<b>(54)</b>	<b>(472)</b>	<b>(3,256)</b>	<b>(176)</b>	<b>(3,958)</b>
<b>Carrying amount:</b>					
December 31, 2018	49	570	2,510	195	3,324
June 30, 2019	85	614	2,722	173	3,594

The Company continues to enhance its laboratory equipment to support its research and development activities. This effort has accelerated since the year ended December 31, 2018, with CHF 0.6 million invested in lab equipment representing a 12% increase. This is consistent with the Company's long term strategic plan.

## 7. Right-of-use assets and lease liabilities

As of January 1, 2019 the Company recognized CHF 2.2 million of right-of-use of leased assets and lease liabilities. Thereof CHF 2.1 million are related to buildings and CHF 0.1 million to office equipment.

During the interim period, the Company recognized depreciation expense of CHF 0.2 million for buildings and an immaterial amount for office equipment. The Company did not recognize additions of right-of-use of leased assets for buildings or for office equipment for the six months ended June 30, 2019. Regarding lease liabilities, the amortization depends on the applied incremental borrowing rate for the respective lease component. The weighted averages of the incremental borrowing rates are 2.5% for buildings and 3.7% for office equipment, respectively.

The following table shows the movements in the net book values of right-of-use of leased assets for the period ended June 30, 2019:

	Buildings	Office Equipment	Total
	(in CHF thousands)		
Balance as of January 1, 2019	2,106	79	2,185
Additions	—	—	—
Disposals	—	—	—
Depreciation	(199)	(8)	(207)
Balance as of June 30, 2019	<b>1,907</b>	<b>71</b>	<b>1,978</b>

The Company's total expense for short-term leases and leases of low-value was CHF 0.1 million and CHF 0.3 million for the three and six months ended June 30, 2019. There are no variable lease payments which are not included in the measurement of lease obligations. All extension options have been included in the measurement of lease obligations.

The following table presents the contractual undiscounted cash flows for lease obligations as of June 30, 2019:

	(in CHF thousands)
Less than one year	466
1 – 3 years	932
3 – 5 years	699
<b>Total</b>	<b>2,097</b>

#### 8. Prepaid expenses

Prepaid expenses include prepaid research and development costs, administrative costs and net employee defined benefit liability expenses totaling CHF 2.9 million and CHF 2.4 million as of June 30, 2019 and December 31, 2018, respectively.

#### 9. Cash and cash equivalents and financial assets

The following table summarizes the Company's cash and cash equivalents and short-term financial assets as of June 30, 2019 and December 31, 2018:

	As of	December 31,
	June 30,	2018
	2019	2018
	(in CHF thousands)	
Cash and cash equivalents	205,735	156,462
<b>Total</b>	<b>205,735</b>	<b>156,462</b>

	As of	December 31,
	June 30,	2018
	2019	2018
	(in CHF thousands)	
Short-term financial assets due in one year or less	80,000	30,000
<b>Total</b>	<b>80,000</b>	<b>30,000</b>

The Company also has two deposits in escrow accounts totaling CHF 0.3 million for the lease of the Company's premises as of June 30, 2019 and December 31, 2018, respectively.

#### 10. Long-term financing obligation

On January 4, 2016, September 13, 2016 and January 26, 2018 for fiscal years 2016, 2017 and 2018, respectively, AC Immune obtained separate funding commitment notices from the LuMind Research Down Syndrome Foundation ("LuMind") totaling USD 200 thousand in each instance. Per the Research Grant Agreement, AC Immune has an obligation to reimburse LuMind for an amount equal to 125% of the then funding commitment made by LuMind to AC Immune.

On October 31, 2018, LuMind and the Company modified the repayment terms in an effort to fund a Down Syndrome Clinical Trials Network. The repayment terms were modified such that the Company will repay the outstanding balance in three installments in 2018, 2019 and 2020, with the total repayment to equal the total the Company is to receive in funding with the additional 25% interest.

The Company reclassified a certain portion of long-term debt obligation from non-current to current liabilities in the balance sheets to reflect the amended repayment terms. Additionally, per this modified payment term, the Company and LuMind memorialized the receipt of one final USD 200 (CHF 197) thousand payment due from LuMind in 2019. The Company has recorded this as a finance receivable and an increase to the obligation accordingly. As of June 30, 2019 and December 31, 2018, we had finance receivables of USD 100 (CHF 98) thousand and USD 200 (CHF 199) thousand, respectively.

As of June 30, 2019 and December 31, 2018, AC Immune has recorded in current liabilities a short-term debt obligation for the total USD 333 (CHF 329) and USD 333 (CHF 332) thousand committed, respectively. As of June 30, 2019 and December 31, 2018, the Company recorded a long-term debt obligation for the total USD 260 (CHF 256) thousand and USD 187 (CHF 186) thousand, respectively.

#### **11. Finance result, net**

For the three months ended June 30, 2019 and June 30, 2018, the Company recorded CHF 2.1 million in net financial losses compared to CHF 0.4 million in net financial gains, respectively. For the three months ended June 30, 2019, CHF 1.2 million related to a loss on the settlement of the convertible loan. The Company also had CHF 0.5 million in interest expense of which CHF 0.4 million was effective interest recorded to amortize the host debt per the convertible loan due to Lilly. Finally, the Company had CHF 0.5 million in foreign currency remeasurement losses.

For the six months ended June 30, 2019 and June 30, 2018, the Company recorded CHF 1.3 million and CHF 0.1 million in net financial gains, respectively. For the six months ended June 30, 2019, CHF 4.5 million related to a gain on the conversion feature of the convertible loan due to Lilly. This gain was offset by CHF 1.2 million related to a loss on the settlement of the convertible loan and CHF 1.6 million in interest expense of which CHF 1.4 million was effective interest recorded to amortize the host debt per the convertible loan due to Lilly. Finally, the Company had CHF 0.6 million in foreign currency remeasurement losses.

#### **12. Subsequent events**

In July 2019, AC Immune and the University of Pennsylvania entered into a collaboration agreement to support research on TDP-43 misfolding and aggregation. Under the terms of the agreement, AC Immune will contribute a two-year research grant.

## MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management's discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed financial information as of and for the three and six months ended June 30, 2019 included as Exhibit 99.1 to this Report on Form 6-K. We also recommend that you read our management's discussion and analysis and our audited financial statements and the notes thereto, which appear in our Annual Report on Form 20-F for the year ended December 31, 2018 on file with the U.S. Securities and Exchange Commission (the "SEC").

Unless otherwise indicated or the context otherwise requires, all references to "AC Immune" or the "Company," "we," "our," "ours," "us" or similar terms refer to AC Immune SA.

We prepare and report our financial statements and financial information in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board (the "IASB"). None of our financial statements were prepared in accordance with generally accepted accounting principles in the United States. We maintain our books and records in Swiss Francs (CHF). We have made rounding adjustments to some of the figures included in this management's discussion and analysis. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that precede them. Unless otherwise indicated, all references to currency amounts in this discussion and analysis are in Swiss Francs.

This discussion and analysis is dated as of August 14, 2019.

### Results of operations

#### Comparison of the three and six months ended June 30, 2019 and 2018

##### Revenues

AC Immune generated revenues of CHF 1.5 million in the three months ended June 30, 2019, a decrease of CHF 0.5 million over the comparable period in 2018. AC Immune generated revenues of CHF 76.6 million in the six months ended June 30, 2019, an increase of CHF 73.1 million over the comparable period in 2018. The following table summarizes our revenues during the three and six months ended June 30, 2019 and 2018:

	For the Three Months Ended June 30,		Change
	2019	2018	
	(in CHF thousands, unaudited)		
Contract revenue	1,511	2,028	(517)
<b>Total revenues</b>	<b>1,511</b>	<b>2,028</b>	<b>(517)</b>

  

	For the Six Months Ended June 30		Change
	2019	2018	
	(in CHF thousands, unaudited)		
Contract revenue	76,553	3,486	73,067
<b>Total revenues</b>	<b>76,553</b>	<b>3,486</b>	<b>73,067</b>

For the three months ended June 30, 2019, the decrease in collaboration revenues compared to the three months ended June 30, 2018 was principally due to recognition of a CHF 1.2 million for Biogen in 2018 that decreased to CHF 0.1 million in 2019 as the collaboration concluded in April 2019. This decrease was offset by CHF 0.4 million recognized for research and development activities associated with our agreement with Lilly to research and develop tau morphomer molecules for the potential treatment of Alzheimer's disease (AD) and other neurodegenerative diseases.



For the six months ended June 30, 2019, the increase in collaboration revenues compared to the six months ended June 30, 2018 was principally due to recognition of a CHF 73.1 million upfront payment for a right-of-use license fee and CHF 1.2 million for research and development activities associated with our agreement to research and develop tau morphomer molecules for the potential treatment of Alzheimer's disease (AD) and other neurodegenerative diseases. There were no similar revenue generating activities in 2018.

#### *Research and development expenses*

Research and development activities are essential to our business and represent the majority of our costs incurred. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using information from the clinical sites and our vendors. Our collaboration arrangements share costs for the development of our product candidates differently. We have completed our research and development spending for both of our Genentech collaborations. From Phase 2b and onwards, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of selected second generation vaccines.

For the three and six months ended June 30, 2019, research and development expenses totaled CHF 12.7 million and CHF 24.3 million compared with CHF 10.5 million and CHF 20.6 million for the comparable periods in 2018, respectively. This represents an increase of CHF 2.2 million and CHF 3.7 million, respectively. The following table presents the research and development expenses during the three and six months ended June 30, 2019 and 2018:

	<b>For the Three Months Ended June 30,</b>		
	<b>2019</b>	<b>2018</b>	<b>Change</b>
	<b>(in CHF thousands, unaudited)</b>		
Operating expenses(1)	9,412	7,698	1,714
Salaries and related costs(2)	3,288	2,835	453
<b>Total research and development expenses</b>	<b>12,700</b>	<b>10,533</b>	<b>2,167</b>

	<b>For the Six Months Ended June 30,</b>		
	<b>2019</b>	<b>2018</b>	<b>Change</b>
	<b>(in CHF thousands, unaudited)</b>		
Operating expenses(1)	17,865	15,233	2,632
Salaries and related costs(2)	6,428	5,371	1,057
<b>Total research and development expenses</b>	<b>24,293</b>	<b>20,604</b>	<b>3,689</b>

(1) Includes depreciation expense

(2) Includes share-based compensation expense

The increase in research and development programs is primarily driven by increased investments in our Anti-Tau vaccines for the treatment of AD and our Tau Morphomers small molecules. The following tables present the research and development expenses by our major development programs during the three and six months ended June 30, 2019 and 2018:

	<b>For the Three Months Ended June 30,</b>		
	<b>2019</b>	<b>2018</b>	<b>Change</b>
	<b>(in CHF thousands, unaudited)</b>		
Alzheimer's disease	4,571	3,962	609
Non-Alzheimer's diseases	862	350	512
Diagnostics	533	769	(236)
New discovery programs	2,838	2,117	721
<b>Total programs</b>	<b>8,804</b>	<b>7,198</b>	<b>1,606</b>
Research and development expenses not allocated to specific programs	3,896	3,335	561
<b>Total</b>	<b>12,700</b>	<b>10,533</b>	<b>2,167</b>

	<b>For the Six Months Ended June 30,</b>		
	<b>2019</b>	<b>2018</b>	<b>Change</b>
	<b>(in CHF thousands, unaudited)</b>		
Alzheimer's disease	8,672	7,695	977
Non-Alzheimer's diseases	1,825	1,125	700
Diagnostics	923	1,140	(217)
New discovery programs	5,140	4,376	764
<b>Total programs</b>	<b>16,560</b>	<b>14,336</b>	<b>2,224</b>
Research and development expenses not allocated to specific programs	7,733	6,268	1,465
<b>Total</b>	<b>24,293</b>	<b>20,604</b>	<b>3,689</b>

The CHF 0.6 million increase in investments in Alzheimer's disease programs for the three months ended June 30, 2019 predominantly relates to a CHF 0.2 million increase for the preparation of the Phase 1b/2a study for ACI-35 and advancement of the vaccine through the development plan as well as a CHF 0.4 million increase for ACI-24 AD related to the preparation of the Phase 2 study. The CHF 0.5 million increase in non-Alzheimer's disease programs predominantly relates to a CHF 0.3 million increase for preclinical activities associated with our morphomer alpha-synuclein program and a CHF 0.2 million increase in ACI-24 in Down Syndrome related to increased manufacturing activities and preparation of the Phase 2 study. The CHF 0.7 million in new discovery programs is driven by a CHF 0.3 million increase for our TDP-43 antibody related to a proof of concept study, a CHF 0.4 million increase for manufacturing activities for our anti-a-Synuclein antibody and a CHF 0.3 million increase for research in our neuroinflammation discovery programs. This was offset by a CHF 0.3 million decrease in other programs.

The CHF 1.0 million increase in investments in Alzheimer's disease programs for the six months ended June 30, 2019 predominantly relates to a CHF 0.9 million increase for the preparation of the Phase 1b/2a study for ACI-35 and advancement of the vaccine through the development plan. The CHF 0.7 million increase in non-Alzheimer's disease programs predominantly relates to a CHF 0.5 million increase for preclinical activities associated with our morphomer alpha-synuclein program and a CHF 0.2 million increase in ACI-24 in Down Syndrome related to increased manufacturing activities and preparation of the Phase 2 study. The CHF 0.8 million in new discovery programs is driven by a CHF 0.3 million increase for our TDP-43 antibody related to a proof of concept study, a CHF 0.3 million increase for research activities for our anti-a-Synuclein antibody and CHF 0.5 million increase for research in our neuroinflammation discovery programs. This was offset by a CHF 0.3 million decrease in other programs.

#### *General and administrative expenses*

General and administrative expenses consist primarily of salaries and related costs, including share-based compensation, professional fees including legal and accounting related services and other operating expenses.

For the three and six months ended June 30, 2019, general and administrative expenses amounted to CHF 3.6 million and CHF 6.9 million compared with CHF 3.1 million and CHF 5.8 million for the comparable periods in 2018, respectively. This represents an increase of CHF 0.5 million and CHF 1.1 million, respectively. The increase is predominantly associated with increases in our payroll expense due to an increase from 15 to 19 FTEs.

For the three months ended June 30, 2019, there was a CHF 0.3 million increase in rental and IT related expenditures offset by a decrease of CHF 0.1 million for professional services. For the six months ended June 30, 2019, there was a CHF 0.7 million increase in rental and IT related expenditures and a CHF 0.3 million increase in investor relations offset by a decrease of CHF 0.2 million for professional services. The remaining CHF 0.3 million increase for the three and six months ended June 30, 2019 are across various other categories and immaterial. The following tables present the general and administrative expenses for the three and six months ended June 30, 2019 and 2018:

	For the Three Months Ended June 30,		
	2019	2018	Change
	(in CHF thousands, unaudited)		
Operating expenses(1)	1,376	1,171	205
Salaries and related costs(2)	2,209	1,894	315
<b>Total general and administrative expenses</b>	<b>3,585</b>	<b>3,065</b>	<b>520</b>

	For the Three Months Ended June 30,		
	2019	2018	Change
	(in CHF thousands, unaudited)		
Operating expenses(1)	2,796	2,127	669
Salaries and related costs(2)	4,083	3,643	440
<b>Total general and administrative expenses</b>	<b>6,879</b>	<b>5,770</b>	<b>1,109</b>

(1) Includes depreciation expense

(2) Includes share-based compensation expense

*Finance result, net*

The following table presents the net financial income and expenses during the three and six months ended June 30, 2019 and 2018:

	For the Three Months Ended June 30,		
	2019	2018	Change
	(in CHF thousands, unaudited)		
Interest expense	(504)	(22)	(482)
Change in fair value of conversion feature	36	—	36
Foreign currency remeasurement gain/(loss), net	(513)	397	(910)
Other finance income/(expense)	(1,144)	52	(1,196)
<b>Finance result, net</b>	<b>(2,125)</b>	<b>427</b>	<b>(2,552)</b>

	For the Six Months Ended June 30,		
	2019	2018	Change
	(in CHF thousands, unaudited)		
Interest expense	(1,601)	(35)	(1,566)
Change in fair value of conversion feature	4,542	—	4,542
Foreign currency remeasurement gain/(loss), net	(558)	195	(753)
Other finance income/(expense)	(1,090)	(27)	(1,063)
<b>Finance result, net</b>	<b>1,293</b>	<b>133</b>	<b>1,160</b>

In the three and six months ended June 30, 2019 and 2018, the Company reported CHF 2.1 million in net financial losses and CHF 1.3 million in net financial gains compared with CHF 0.4 million and CHF 0.1 million in net financial gains for the comparable periods in 2018, respectively. This represents a difference of CHF 2.6 million and CHF 1.2 million, respectively.

The key drivers for the financial losses during the three months ended June 30, 2019 relate to an increase of 0.4 million in effective interest to amortize the host debt for the convertible loan. The Company also recorded a CHF 1.2

million loss associated with the revaluation of the convertible loan prior to its settlement in April 2019. Finally, as the USD weakened against the Swiss Franc through the second quarter, the Company recorded a CHF 0.5 million foreign currency loss compared to a 0.4 million foreign currency gain in the comparable period.

The key drivers for the financial gains during the six months ended June 30, 2019 relate to a CHF 4.5 million change in the fair value of the conversion feature for the convertible loan due to Lilly. This gain was offset by CHF 1.6 million in interest expense, of which CHF 1.4 million is effective interest to amortize the host debt for the convertible loan. The Company also recorded a CHF 1.2 million loss associated with the revaluation of the convertible loan prior to its settlement in April 2019. Finally, as the USD weakened against the Swiss Franc through the second quarter, the Company recorded a CHF 0.6 million foreign currency loss compared to a 0.2 million foreign currency gain in the comparable period.

#### *Liquidity and capital resources*

To date, the Company has financed its cash requirements primarily from its public offerings, share issuances and revenues from collaboration agreements. The Company is a clinical stage company and is exposed to all the risks inherent to establishing a business. Inherent to the Company's business are various risks and uncertainties, including the substantial uncertainty as to whether current projects will succeed. As of June 30, 2019, we had cash and cash equivalents of CHF 206 million and short-term financial assets of CHF 80 million for a total liquidity balance of CHF 286 million.

Our primary uses of capital are, and we expect will continue to be, research and development expenses, compensation and related expenses, and other operating expenses including rent. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding trade and other payables and accrued expenses. We expect to incur expenses in connection with a number of our product candidates in various stages of clinical development including co-funding ACI-35 to the end of the Phase 1b/2a clinical study, expenditures for clinical activities in accordance with our agreement with Lilly, ACI-24 in AD and ACI-24 in Down syndrome, our PET tracer candidates focused on alpha-synuclein and TDP-43 and a number of research initiatives focused on neurodegenerative orphan diseases other than AD.

We plan to continue to fund our operating and capital funding needs through proceeds received from licensing and collaboration agreements and through equity or other forms of financing. We may also consider entering into additional collaboration agreements and selectively partnering for clinical development and commercialization.

#### *Cash flows*

The following table summarizes our cash flows for the periods indicated:

	<b>For the Six Months Ended June 30,</b>		<b>Change</b>
	<b>2019</b>	<b>2018</b>	
	<b>(in CHF thousands, unaudited)</b>		
Net cash provided by (used in):			
Operating activities	50,949	(20,481)	71,430
Investing activities	(50,850)	(1,570)	(49,280)
Financing activities	49,732	143	49,589
<b>Net change in cash and cash equivalents</b>	<b>49,831</b>	<b>(21,908)</b>	<b>71,739</b>

#### *Operating activities*

Net cash provided by operating activities was CHF 50.9 million for the six months ended June 30, 2019 compared with net cash used in operating activities of CHF 20.5 million for the six months ended June 30, 2018. The change in cash provided by operating activities for the six months ended June 30, 2019 was due to the Company's reporting net income of CHF 46.7 million for the six months ended June 30, 2019 compared with net loss of CHF 22.8 million for the same period in 2018 driven by (i) an increase of CHF 73.1 million in revenues principally due to recognition of a CHF 73.1 million upfront payment for a right-of-use license fee and CHF 1.2 million for research and development activities associated with our agreement with Lilly (ii) offset by the increase in research and development costs in the six months ended June 30, 2019.

### *Investing activities*

Net cash used in investing activities rose to CHF 50.9 million for the six months ended June 30, 2019 compared with net cash used in investing activities of CHF 1.6 million for the six months ended June 30, 2018 due to CHF 50.0 million increase in fixed-term deposits with maturities of six to 12 months as well as a CHF 0.9 million investment in capital expenditures to strengthen our manufacturing and research infrastructure.

### *Financing activities*

Net cash provided by financing activities was CHF 49.7 million for the six months ended June 30, 2019 compared with net cash provided by financing activities of CHF 0.1 million for the six months ended June 30, 2018. The increase of CHF 49.6 million is predominantly related to CHF 50.3 million received from Lilly for a convertible loan offset by CHF 0.5 million for transaction costs associated with loan settlement.

### *Operating capital requirements and plan of operations*

We do not expect to generate revenues from royalties based on product sales unless and until our partners obtain regulatory approval of, and successfully commercialize, our current or any future product candidates. As of June 30, 2019, we had cash and cash equivalents of CHF 206 million and short-term financial assets of CHF 80 million totaling CHF 286 million in liquidity. The increase relative to December 31, 2018 is due to the receipt of a CHF 80 million upfront payment from Lilly as well as USD 50 (CHF 50.3) million in consideration for the convertible note agreement. These increases in cash receipts were offset by an increase in research and development spending on our major discovery, research and development programs and the strengthening of the Company's infrastructure, systems and organization. There can be no certainty as to the exact timing, or in fact, whether any future milestone payments will ever be made given that these milestone payments are contingent on clear milestones being reached. Accordingly, assuming we do not receive potential milestone payments and based upon our currently contemplated research and development strategy, we believe that our existing capital resources will be sufficient to meet our projected operating requirements through the third quarter of 2023.

We expect to generate losses for the foreseeable future, and these losses could increase as we continue product development until we successfully achieve regulatory approvals for our product candidates and begin to commercialize any approved products. We are subject to all the risks pertinent to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may harm our business. We expect to incur additional costs associated with operating a public company and we anticipate that we will need substantial additional funding in connection with our continuing operations. If we need to raise additional capital to fund our operations and complete our ongoing and planned clinical studies, funding may not be available to us on acceptable terms, or at all.

Our future funding requirements will depend on many factors, including but not limited to the following:

- The scope, rate of progress, results and cost of our pre-clinical and clinical studies and other related activities, according to our long-term strategic plan;
- The cost of manufacturing clinical supplies and establishing commercial supplies of our product candidates and any other products we may develop;
- The cost, timing and outcomes of regulatory approvals;
- The costs and timing of establishing sales, marketing and distribution capabilities;
- The terms and timing of any collaborative, licensing and other arrangements that we may establish, including any required milestone and royalty payments thereunder;
- The emergence of competing technologies or other adverse market developments; and
- The potential cost and timing of managing, protecting, defending and enforcing our portfolio of intellectual property.

### *Quantitative and qualitative disclosures about market risk*

During the three and six months ended June 30, 2019, there were no significant changes to our quantitative and qualitative disclosures about market risk described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Quantitative and Qualitative Disclosures About Market Risk” in the Annual Report on Form 20-F.

### *Critical judgments and accounting estimates*

There have been no material changes to the significant accounting policies and estimates described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Judgments and Accounting Estimates” in the Annual Report on Form 20-F.

### *JOBS Act exemption*

On April 5, 2012, the Jumpstart our Business Startups Act of 2012, or the JOBS Act, was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an “emerging growth company.” As an emerging growth company, we are not required to provide an auditor attestation report on our system of internal controls over financial reporting. This exemption will apply for a period of five years following the completion of our initial public offering (through 2021) or until we no longer meet the requirements of being an “emerging growth company,” whichever is earlier. We would also cease to be an emerging growth company if (i) we have more than USD 1.07 billion in annual revenue, ii) we are deemed to be a “large accelerated filer” under the rules of the SEC, which means the market value of our common shares that are held by non-affiliates exceeds USD 700 million as of the most recently completed second fiscal quarter, or (iii) we have issued more than USD 1.0 billion in non-convertible debt during the prior three-year period.

### **Non-IFRS Financial Measures**

In addition to our operating results, as calculated in accordance with International Financial Reporting Standards, or IFRS, as adopted by the International Accounting Standards Board, we use adjusted income/(loss) and adjusted earnings/(loss) per share when monitoring and evaluating our operational performance. Adjusted income/(loss) is defined as income/(loss) for the relevant period, as adjusted for certain items that we believe are not indicative of our ongoing operating performance. Adjusted earnings/(loss) per share is defined as adjusted income/(loss) for the relevant period divided by the weighted-average number of shares for such period.

We believe that these measures assist our shareholders because they enhance comparability of our results each period and provide more useful insight into operational results for the period. The Company’s executive management uses these non-IFRS measures to evaluate our operational performance. These non-IFRS financial measures are not meant to be considered alone or as substitutes for our IFRS financial measures and should be read in conjunction with AC Immune’s financial statements prepared in accordance with IFRS. The most directly comparable IFRS measure to these non-IFRS measures is net income/(loss). The following table reconciles net income/(loss) to adjusted income/(loss) and adjusted earnings/(loss) per share for the periods presented:

**Reconciliation of Income/(Loss) to Adjusted Income/(Loss) and  
Earnings/(Loss) Per Share to Adjusted Earnings/(Loss) Per Share**

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2019	2018	2019	2018
	(in CHF thousands except for share and per share data)			
<b>Income/(Loss)</b>	<b>(16,899)</b>	<b>(11,143)</b>	<b>46,674</b>	<b>(22,755)</b>
<b>Adjustments:</b>				
Non-cash share-based payments (a)	561	712	1,146	1,314
Foreign currency losses (b)	513	(397)	558	(195)
Effective interest expense (c)	364	—	1,355	—
Change in fair value of conversion feature (d)	(36)	—	(4,542)	—
<b>Adjusted Income/(Loss)</b>	<b>(15,497)</b>	<b>(10,828)</b>	<b>45,191</b>	<b>(21,636)</b>
<b>Earnings/(Loss) per share – basic</b>	<b>(0.24)</b>	<b>(0.19)</b>	<b>0.67</b>	<b>(0.40)</b>
<b>Earnings/(Loss) per share – diluted</b>	<b>(0.24)</b>	<b>(0.19)</b>	<b>0.67</b>	<b>(0.40)</b>
<b>Adjustment to earnings/(loss) per share – basic</b>	<b>0.02</b>	<b>0.00</b>	<b>(0.02)</b>	<b>0.02</b>
<b>Adjustment to earnings/(loss) per share – diluted</b>	<b>0.02</b>	<b>0.00</b>	<b>(0.02)</b>	<b>0.02</b>
<b>Adjusted earnings/(loss) per share – basic</b>	<b>(0.22)</b>	<b>(0.19)</b>	<b>0.65</b>	<b>(0.38)</b>
<b>Adjusted earnings/(loss) per share – diluted</b>	<b>(0.22)</b>	<b>(0.19)</b>	<b>0.65</b>	<b>(0.38)</b>
Weighted-average number of shares used to compute Adjusted earnings/(loss) per share – basic	70,764,091	57,423,650	69,351,363	57,395,987
Weighted-average number of shares used to compute Adjusted earnings/(loss) per share – diluted	70,764,091	57,423,650	69,845,858	57,395,987

- (a) Reflects non-cash expenses associated with share-based compensation for equity awards issued to Directors, Management and employees of the Company. This expense reflects the awards' fair value recognized for the portion of the equity award which is vesting over the period.
- (b) Reflects foreign currency remeasurement gains and losses for the period, predominantly impacted by the change in the exchange rate between the US Dollar and the Swiss Franc.
- (c) Effective interest expense for the period relates to the accretion of the Company's convertible loan in accordance with the effective interest method.
- (d) Change in fair value of conversion feature that is bifurcated from the convertible loan host debt with Lilly.

For the three and six months ended June 30, 2019, adjustments decreased net loss and net income by CHF 1.4 million and CHF 1.5 million compared with decreases to the net losses by CHF 0.3 million and CHF 1.1 million for the comparable periods in 2018, respectively. The Company recorded CHF 0.6 million and CHF 1.1 million for the three and six months, respectively, for share-based compensation expenses. There were foreign currency remeasurement losses of CHF 0.5 million and 0.6 million, respectively, predominantly related to foreign currency fluctuations. The Company recorded CHF 0.4 million and CHF 1.4 million for amortization of effective interest for the three and six months ended June 30, 2019, respectively. Finally, the Company recognized less than a CHF 0.1 million and a CHF 4.5 million gain for the change in fair value of the liability related to the conversion feature.

### ***Cautionary Statement Regarding Forward Looking Statements***

This discussion and analysis contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this discussion and analysis, including statements regarding our future results of operations and financial position, business strategy, product candidates, product pipeline, ongoing and planned clinical studies, including those of our collaboration partners, regulatory approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Many of the forward-looking statements contained in this prospectus can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate,” “will” and “potential,” among others. Forward-looking statements appear in a number of places in this discussion and analysis and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified under the section entitled “Risk Factors” in our annual report on Form 20-F. These forward-looking statements speak only as of the date of this discussion and analysis and are subject to a number of risks, uncertainties and assumptions described under the sections in the our annual report on Form 20-F entitled “Risk Factors” and this discussion and analysis. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.





## AC Immune Reports Q2 2019 Financial Results, Business and Clinical Update

### *Company Outlines Roadmap to Develop Successful Therapies for Neurodegenerative Diseases Based on its Broad Anti-Tau Clinical Pipeline*

**Lausanne, Switzerland, August 14, 2019** – AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced its business and clinical plan and strategy, reported consolidated financial results for the second quarter of 2019 and its revised cash guidance.

Prof. Andrea Pfeifer, Ph.D., CEO of AC Immune, commented: “Our business strategy is based on a three-pillar approach in the development of treatments for Alzheimer’s disease, NeuroOrphan therapeutics and diagnostics. Our *Roadmap to Successful Therapies for Neurodegenerative Diseases* is based on treating earlier, targeting Tau, incorporating homogeneous populations, applying precision medicine and targeting neuroinflammation.”

There is a growing body of clinical evidence that Tau drives disease progression. AC Immune has one of the broadest anti-Tau pipelines with antibodies, small molecules, vaccines and diagnostics, covering five clinical trials and partnerships with four major pharmaceutical companies.

“SupraAntigen™ and Morphomer™, our proprietary discovery platforms are the foundation for multiple product candidates, added Dr. Pfeifer. “The productivity of these platforms has recently demonstrated significant clinical, value-creating milestones.”

#### **Research & Development Highlights Q2 2019 and Beyond**

- Dosing of the first subject in a Phase 1 study of ACI-3024, a first-in-class investigational oral small molecule Tau Morphomer™ inhibitor that will be studied in neurodegenerative diseases that are characterized by the presence of pathological Tau aggregates. This is the first significant advancement in AC Immune’s collaboration with Eli Lilly and Company
- Initiation of a Phase 1b/2a clinical trial to evaluate ACI-35.030, a clinically advanced anti-phospho-Tau designed to reduce and to prevent the spread and development of Tau pathology to treat early and moderate Alzheimer’s disease (AD)
- Initial interim data from an ongoing Phase 1b trial of AC Immune’s ACI-24 anti-Abeta vaccine, to treat AD like symptoms in subjects with Down syndrome (DS), demonstrated strong safety and preliminary immunogenicity results
- Hosted a Key Opinion Leader (KOL) event, where presentations underscored the significant need and opportunity for studying AD-like symptoms in DS, a high-risk and genetically homogeneous population
- Initiation of a substudy by Genentech, a member of the Roche Group, in the ongoing Phase 2 Alzheimer’s Prevention Initiative (API) trial of AC Immune’s investigational candidate, crenezumab. The substudy, which measures Tau burden using Positron Emission Tomography (PET), aims to increase the understanding of disease progression in the preclinical stage of autosomal dominantly inherited, or familial, AD
- Initiation of a research partnership with leading scientists in the Perelman School of Medicine at the University of Pennsylvania (Penn) focused on studying the pathological mechanisms of TDP-43 misfolding and aggregation

## Anticipated Near-Term Milestones

- H2:2019: Proof-of-concept data from three NeuroOrphan indications from our SupraAntigen™ platform
- H2:2020: Read out from a Phase 2 clinical trial in prodromal/mild AD patients from the SupraAntigen™ platform
- Multiple clinical trial readouts from collaboration partners in 2020/2021 confirming Tau antibodies as a viable approach to halting the progression of AD and other neurodegenerative conditions

## Analysis of Financial Statements for the Three and Six Months Ended June 30, 2019

- **Cash Position:** The Company had a total cash balance of CHF 285.7 million, comprised of CHF 205.7 million in cash and cash equivalents and CHF 80.0 million in short-term financial assets. This compares to a total cash balance of CHF 186.5 million as of December 31, 2018. The increase of CHF 99.2 million is principally due to the CHF 80 million upfront payment and USD 50 million convertible equity note related to the agreement with Lilly. Further details are available in our Statements of Cash Flows in the accompanying Form 6-K. The total shareholders' equity position increased from December 31, 2018 to CHF 273.3 million from CHF 177.6 million. Further details are available in our corresponding Financial Statements filed on the accompanying Form 6-K.
- **Revenues:** Revenues for the three and six months ended June 30, 2019 totaled CHF 1.5 million and CHF 76.6 million, respectively. This represents a decrease of CHF 0.5 million and increase of CHF 73.1 million compared to the respective periods in 2018. The decrease for the three-month period relates to 2018 Biogen revenues not repeated in 2019, as this contract concluded in April. The increase for the six-month period is driven by the recognition of CHF 74.3 million from the right-of-use license and research and development activities linked to the 2018 Lilly agreement. Revenues fluctuate as a result of payments associated with our collaborations with current and potential new partners, the timing of milestone achievements and the size of each milestone payment.
- **R&D Expenditures:** R&D expenditures increased by CHF 2.2 million (+21%) and CHF 3.7 million (+18%) for the three and six months ended June 30, 2019 compared to the comparable periods in 2018, respectively. The Company largely increased its investments in AD, non-AD and new discovery programs. For AD, the Company prepared activities for its Phase 1b/2a and Phase 2 studies for ACI-35 and ACI-24 AD, respectively. For non-AD, the Company increased investment in its Morphomer™ alpha-synuclein programs and continued to advance ACI-24 DS through clinical development. Finally, in new discovery, the Company continues to focus on its neuroinflammation discovery programs.
- **G&A Expenses:** For the three and six months ended June 30, 2019, G&A increased CHF 0.5 million (+17%) and CHF 1.1 million (+19%) to CHF 3.6 million and CHF 6.9 million, respectively. Increases are driven by rental, personnel and IT expenses.
- **IFRS Income/(Loss) for the period:** The Company incurred net loss and net income after taxes of CHF 16.9 million and CHF 46.7 million for the three and six months ended June 30, 2019, respectively, compared with net losses of CHF 11.1 million and CHF 22.8 million for the comparable periods in 2018.

## **About AC Immune**

AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in Precision Medicine for neurodegenerative diseases. The Company is utilizing two proprietary discovery platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Lilly and Janssen Pharmaceuticals Inc.

As a strategic leader in the field of neurodegenerative diseases, AC Immune has developed a five point *Roadmap to Successful Therapies for Neurodegenerative Diseases* that recognizes the importance of treating earlier, targeting Tau, focusing on more homogeneous populations, precision medicine and exploring neuroinflammation as a target.

## **For further information, please contact:**

### **U.S. Investors**

Joshua Drumm, Ph.D.  
AC Immune Investor Relations  
Phone: +1 646 876 5538  
E-mail: [joshua.drumm@acimmune.com](mailto:joshua.drumm@acimmune.com)

### **U.S. Media**

Katie Gallagher  
LaVoieHealthScience  
Phone: +1 617 792 3937  
E-mail: [kgallagher@lavoiehealthscience.com](mailto:kgallagher@lavoiehealthscience.com)

### **European Media**

Judith Moore  
AC Immune Global Communication Lead  
Phone: +44 7932 053829  
Email: [judith.moore@acimmune.com](mailto:judith.moore@acimmune.com)

### **European Investors**

Chris Maggos  
LifeSci Advisors  
Phone: +41 79 367 6254  
E-mail: [chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)

## **Forward-looking statements**

This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information—Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

## Balance Sheets

	As of June 30, 2019	As of December 31, 2018
in CHF thousands		
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	3,594	3,324
Right-of-use assets	1,978	-
Long-term financial assets	304	304
<b>Total non-current assets</b>	<b>5,876</b>	<b>3,628</b>
<b>Current assets</b>		
Prepaid expenses	2,917	2,364
Accrued income	547	3,667
Finance receivable	98	199
Other current receivables	1,049	236
Short-term financial assets	80,000	30,000
Cash and cash equivalents	205,735	156,462
<b>Total current assets</b>	<b>290,346</b>	<b>192,928</b>
<b>Total assets</b>	<b>296,222</b>	<b>196,556</b>
<b>SHAREHOLDERS' EQUITY AND LIABILITIES</b>		
<b>Shareholders' equity</b>		
Share capital	1,436	1,351
Share premium	346,024	298,149
Accumulated losses	(74,170)	(121,877)
<b>Total shareholders' equity</b>	<b>273,290</b>	<b>177,623</b>
<b>Non-current liabilities</b>		
Long-term financing obligation	256	186
Long-term lease liabilities	1,559	-
Long-term deferred income	1,903	-
Net employee defined benefit liabilities	5,954	5,665
<b>Total non-current liabilities</b>	<b>9,672</b>	<b>5,851</b>
<b>Current liabilities</b>		
Trade and other payables	156	1,979
Accrued expenses	8,414	10,420
Short-term deferred income	3,941	351
Short-term debt obligation	329	332
Short-term lease liabilities	420	-
<b>Total current liabilities</b>	<b>13,260</b>	<b>13,082</b>
<b>Total liabilities</b>	<b>22,932</b>	<b>18,933</b>
<b>Total shareholders' equity and liabilities</b>	<b>296,222</b>	<b>196,556</b>

## Statements of Income/(Loss)

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2019	2018	2019	2018
	(in CHF thousands except for per share data)			
<b>Revenue</b>				
Contract revenue	1,511	2,028	76,553	3,486
<b>Total revenue</b>	<b>1,511</b>	<b>2,028</b>	<b>76,553</b>	<b>3,486</b>
<b>Operating expenses</b>				
Research & development expenses	(12,700)	(10,533)	(24,293)	(20,604)
General & administrative expenses	(3,585)	(3,065)	(6,879)	(5,770)
<b>Total operating expenses</b>	<b>(16,285)</b>	<b>(13,598)</b>	<b>(31,172)</b>	<b>(26,374)</b>
<b>Operating income/(loss)</b>	<b>(14,774)</b>	<b>(11,570)</b>	<b>45,381</b>	<b>(22,888)</b>
Finance income / (expense), net	(1,732)	447	(1,812)	165
Change in fair value of conversion feature	36	—	4,542	—
Interest income	75	2	164	3
Interest expense	(504)	(22)	(1,601)	(35)
<b>Finance result, net</b>	<b>(2,125)</b>	<b>427</b>	<b>1,293</b>	<b>133</b>
<b>Income/(loss) before tax</b>	<b>(16,899)</b>	<b>(11,143)</b>	<b>46,674</b>	<b>(22,755)</b>
<b>Income tax expense</b>	<b>—</b>	<b>—</b>	<b>—</b>	<b>—</b>
<b>Income/(loss) for the period</b>	<b>(16,899)</b>	<b>(11,143)</b>	<b>46,674</b>	<b>(22,755)</b>
Income/(loss) per share (EPS):				
Basic income/(loss) for the period attributable to equity holders	(0.24)	(0.19)	0.67	(0.40)
Diluted income/(loss) for the period attributable to equity holders	(0.24)	(0.19)	0.67	(0.40)

## Statements of Comprehensive Income/(Loss)

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2019	2018	2019	2018
	(in CHF thousands)			
Income/(loss) for the period	(16,899)	(11,143)	46,674	(22,755)
Other comprehensive income/(loss) not to be reclassified to income or loss in subsequent periods (net of tax):				
Re-measurement losses on defined benefit plans	—	—	—	—
<b>Total comprehensive income/(loss), net of tax</b>	<b>(16,899)</b>	<b>(11,143)</b>	<b>46,674</b>	<b>(22,755)</b>

**Reconciliation of Income/(Loss) to Adjusted Income/(Loss) and  
Earnings/(Loss) Per Share to Adjusted Earnings/(Loss) Per Share**

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2019	2018	2019	2018
	(in CHF thousands except for share and per share data)			
<b>Income/(Loss)</b>	<b>(16,899)</b>	<b>(11,143)</b>	<b>46,674</b>	<b>(22,755)</b>
<b>Adjustments:</b>				
Non-cash share-based payments (a)	561	712	1,146	1,314
Foreign currency losses (b)	513	(397)	558	(195)
Effective interest expense (c)	364	—	1,355	—
Change in fair value of conversion feature (d)	(36)	—	(4,542)	—
<b>Adjusted Income/(Loss)</b>	<b>(15,497)</b>	<b>(10,828)</b>	<b>45,191</b>	<b>(21,636)</b>
<b>Earnings/(Loss) per share – basic</b>	<b>(0.24)</b>	<b>(0.19)</b>	<b>0.67</b>	<b>(0.40)</b>
<b>Earnings/(Loss) per share – diluted</b>	<b>(0.24)</b>	<b>(0.19)</b>	<b>0.67</b>	<b>(0.40)</b>
<b>Adjustment to earnings/(loss) per share – basic</b>	<b>0.02</b>	<b>0.00</b>	<b>(0.02)</b>	<b>0.02</b>
<b>Adjustment to earnings/(loss) per share – diluted</b>	<b>0.02</b>	<b>0.00</b>	<b>(0.02)</b>	<b>0.02</b>
<b>Adjusted earnings/(loss) per share – basic</b>	<b>(0.22)</b>	<b>(0.19)</b>	<b>0.65</b>	<b>(0.38)</b>
<b>Adjusted earnings/(loss) per share – diluted</b>	<b>(0.22)</b>	<b>(0.19)</b>	<b>0.65</b>	<b>(0.38)</b>
Weighted-average number of shares used to compute Adjusted earnings/(loss) per share – basic	70,764,091	57,423,650	69,351,363	57,395,987
Weighted-average number of shares used to compute Adjusted earnings/(loss) per share – diluted	70,764,091	57,423,650	69,845,858	57,395,987

- (a) Reflects non-cash expenses associated with share-based compensation for equity awards issued to Directors, Management and employees of the Company. This expense reflects the awards' fair value recognized for the portion of the equity award which is vesting over the period.
- (b) Reflects foreign currency remeasurement gains and losses for the period, predominantly impacted by the change in the exchange rate between the US Dollar and the Swiss Franc.
- (c) Effective interest expense for the period relates to the accretion of the Company's convertible loan in accordance with the effective interest method.
- (d) Change in fair value of conversion feature that is bifurcated from the convertible loan host debt with Lilly.

For the three and six months ended June 30, 2019, adjustments decreased net loss and net income by CHF 1.4 million and CHF 1.5 million compared with decreases to the net losses by CHF 0.3 million and CHF 1.1 million for the comparable periods in 2018, respectively. The Company recorded CHF 0.6 million and CHF 1.1 million for the three and six months, respectively, for share-based compensation expenses. There were foreign currency remeasurement losses of CHF 0.5 million and 0.6 million, respectively, predominantly related to foreign currency fluctuations. The Company recorded CHF 0.4 million and CHF 1.4 million for amortization of effective interest for the three and six months ended June 30, 2019, respectively. Finally, the Company recognized less than a CHF 0.1 million and a CHF 4.5 million gain for the change in fair value of the liability related to the conversion feature.